Stmm’s Continuous Bioreactor Increases Antibody Productivity by up to 30x in European and American Pilots | PR Newswire [Video]

Pilot runs in Europe and South America show breakthrough efficiency in monoclonal antibody production with unprecedented cost savings and scalability using Stämm’s bubble-free continuous laminar flow bioreactor: the Bioprocessor.

, /PRNewswire/ — Stämm unveiled breakthrough results of its continuous bioreactor for monoclonal antibody production with pilot studies in Germany, Switzerland, and Argentina. It achieved a minimum of 15x greater volumetric productivity, projecting up to 50x during 2025. It also consistently evidenced up to 4x cellular density and specific productivity. The Bioprocessor, a plug-and-play desktop unit, cuts costs compared to traditional fed-batch systems and eliminates downtime while maintaining quality, working with both adherent and suspension cultures.

As healthcare faces an increasing demand for therapies, Stämm enables the commercialization of biosimilars and different biologics for chronic and complex diseases such as oncology, inflammation, and immunology-related diseases. The biomanufacturing process for cell and gene therapies also benefits thanks to a high surface to volume ratio, …